Dexamethasone for ocular inflammation

Saraiya, Nehali V.; Goldstein, Debra A.

doi:10.1517/14656566.2011.571209

Cited by 60 publications

(40 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Indeed, the dexamethasone implant resulted in sustained levels of dexamethasone and biological activity for 6 months, with peak levels of drug over the first 3 months. [17][18][19] The target population in the current study was difficult to treat because it included severe cases of long-standing ME after cataract surgery that had failed to respond to previous wide range of treatment options including oral CAIs, topical combination therapy with NSAIDs and corticosteroids, as well as intravitreal treatment, most commonly intravitreal injection of the corticosteroid TA or the anti-VEGF therapy. The mean duration of CME before treatment with Ozurdex (Allergan, Inc.) was 9.1 months (range, 6-13 months).…”

Section: Discussionmentioning

confidence: 99%

Dexamethasone Intravitreal Implant for Treatment of Patients With Recalcitrant Macular Edema Resulting From Irvine-Gass Syndrome

Dutra-Medeiros

Navarro

García‐Arumí

et al. 2013

Invest. Ophthalmol. Vis. Sci.

View full text Add to dashboard Cite

PURPOSE.To evaluate the effectiveness of a single intravitreal injection of dexamethasone implant, over 6 months in patients with recalcitrant CME due to Irvine-Gass syndrome.METHODS. Retrospective review of the medical records of nine patients with refractory macular edema (ME) due to Irvine-Gass syndrome, who underwent a single intravitreal injection of dexamethasone implant, Ozurdex, between November 2010 and January 2012, at the Instituto de Microcirurgia Ocular, Barcelona, Spain. All patients underwent a complete ophthalmic evaluation, including best-corrected visual acuity (BCVA) using standardized ETDRS charts, tonometry, fluorescein angiography, and spectral-domain optical coherence tomography with foveal thickness (FT) measurement.RESULTS. The mean duration of CME before treatment with Ozurdex was 9.1 months (range, 6-13 months). At baseline, the mean FT was 542.22 6 134.78 lm. Mean (SD) values of FT did decrease to 350.88 6 98.71 lm (P ¼ 0.001) at month 1 and 319.22 6 60.96 lm (P ¼ 0.002) at month 3. Data on the 6-month follow-up showed a mild increase 398.33 6 127.89 lm (P ¼ 0.031). The mean (SD) change from baseline FT was 191.33 lm (a decrease value of 35%) at month 1, and 223.00 lm (decrease value of 41%) and 143.89 lm (decrease value of 26%) at month 3 and month 6, respectively. The baseline BCVA data were 0.62 6 0.15 logarithm of the minimum angle of resolution (logMAR). The mean BCVA improved to 0.47 6 0.21 logMAR (P ¼ 0.008) and 0.37 6 0.24 logMAR (P ¼ 0.001) after month 1 and month 3, respectively. At the last visit (6-month follow-up), the mean BCVA was 0.37 6 0.26 logMAR (P ¼ 0.002).CONCLUSIONS. In this study, both mean FT and mean BCVA had improved from baseline by 1 month after treatment with a dexamethasone implant, and the improvement remained statistically significant throughout the 6-month study.

show abstract

Section: Discussionmentioning

confidence: 99%

Dexamethasone Intravitreal Implant for Treatment of Patients With Recalcitrant Macular Edema Resulting From Irvine-Gass Syndrome

Dutra-Medeiros

Navarro

García‐Arumí

et al. 2013

Invest. Ophthalmol. Vis. Sci.

View full text Add to dashboard Cite

show abstract

“…However, there is evidence for efficacy in multiple clinical situations, including DME, ME associated with uveitis or Irvine-Gass syndrome, DME in vitrectomized eyes, persistent ME and noninfectious vitritis [13,14,15,16,17,18,19,20]. Dexamethasone implantation resulted in sustained levels of dexamethasone and biological activity for 6 months, with peak levels of drug over the first 2 months [16,17,18]. Compared with published data describing other routes of administration of dexamethasone analogues, several results demonstrate a few advantages of this implant [21].…”

Section: Introductionmentioning

confidence: 99%

Dexamethasone Intravitreal Implant for Treatment of Patients with Persistent Diabetic Macular Edema

Dutra-Medeiros

Postorino²,

Navarro³

et al. 2013

Ophthalmologica

View full text Add to dashboard Cite

Purpose: To report the 6-month anatomical and best-corrected visual acuity (BCVA) response after primary intravitreal dexamethasone implantation (Ozurdex®) in patients with refractory diabetic macular edema (DME). Methods: Retrospective review of the medical records of 58 patients with decreased visual acuity, due to refractory DME, who underwent a single injection of Ozurdex between November 2010 and January 2012, at the Instituto de Microcirurgia Ocular, Barcelona, Spain. Results: At baseline, the mean foveal thickness (FT) was 543.24 ± 156.51 μm. Mean (±SD) values of FT did decrease to 346.82 ± 123.74 μm at month 1 and 341.12 ± 129.64 μm at month 3. Data on the 6-month follow-up showed a mild increase to 420.16 ± 152.15 μm. All of the FT reduction outcomes were statistically significant, with respect to baseline data (p = 0.0001). The baseline BCVA data was 0.66 ± 0.36 logarithm of the minimum angle of resolution (logMAR). The mean BCVA improved to 0.52 ± 0.32 logMAR (p = 0.0001) and 0.44 ± 0.27 logMAR (p = 0.0001) after 1 and 3 months, respectively. At the last visit (6-month follow-up), the mean BCVA increased to 0.51 ± 0.31 logMAR (p = 0.0001). Conclusions: In this study, intravitreal treatment with a dexamethasone implant safely reduced DME and improved visual acuity in a difficult-to-treat patient population with long-standing refractory DME.

show abstract

“…Ozurdex was recently approved by the United States Food and Drug Administration and by the European Union and is licensed in all EU countries for the treatment of adult patients with ME following retinal vein occlusion. However, there is evidence for efficacy in multiple clinical situations, including DME, ME associated with uveitis or Irvine-Gass syndrome, DME in vitrectomized eyes, persistent ME, noninfectious vitritis, and as adjunctive therapy for age-related macular degeneration [10,11,12,13,14,15,16,17,18]. …”

Section: Introductionmentioning

confidence: 99%

Intravitreal Dexamethasone Implant in Patients with Persistent Diabetic Macular Edema

et al. 2012

View full text Add to dashboard Cite

Purpose: To evaluate the effects of a single injection of Ozurdex over 6 months in eyes with persistent diabetic macular edema (DME). Methods: In this retrospective interventional study, 9 patients with decreased visual acuity, as a result of persistent DME, received Ozurdex (intravitreal dexamethasone implant 0.7 mg). Main outcome measures included changes in best-corrected visual acuity (BCVA) and central retinal thickness (CRT). Results: Nine eyes of 9 patients (5 males, 4 females; mean age 58 years) were included in the analysis. The mean duration of DME was 49.9 months (range 24–85). All patients had undergone previous treatments for DME (intravitreal injection of anti-vascular endothelial growth factor, steroids or laser photocoagulation) before entering the study. At baseline, the mean BCVA was 0.74 ± 0.33 logMAR, and the mean CRT was 502 ± 222.16 µm. The mean BCVA was unchanged on the third day (0.74 ± 0.38 logMAR, p = 0.5), improved to 0.62 ± 0.32 logMAR (p = 0.02), 0.59 ± 0.26 logMAR (p = 0.02) and 0.63 ± 0.38 logMAR (p = 0.6) after the first, third and fourth months, respectively, and decreased again to 0.73 ± 0.35 logMAR (p = 0.4) at 6 months. The mean CRT improved to 397 ± 115.31 µm (p = 0.17), 271 ± 99.97 µm (p = 0.007), 325 ± 133.05 µm (p = 0.03) and 462 ± 176.48 µm (p = 0.36) on the third day and after 1, 3 and 4 months of follow-up and then increased again to 537 ± 265.42 µm (p = 0.33) at 6 months. Eight patients needed retreatments in the sixth month. One eye developed a transient intraocular pressure (IOP) increase 1 month after injection, which was successfully managed with topical IOP-lowering medication. Conclusion: In eyes with persistent DME, Ozurdex produces improvement in BCVA and CRT as soon as the first days after the injection. Such improvement is maintained until the fourth month.

show abstract

Dexamethasone for ocular inflammation

Cited by 60 publications

References 17 publications

Dexamethasone Intravitreal Implant for Treatment of Patients With Recalcitrant Macular Edema Resulting From Irvine-Gass Syndrome

Dexamethasone Intravitreal Implant for Treatment of Patients With Recalcitrant Macular Edema Resulting From Irvine-Gass Syndrome

Dexamethasone Intravitreal Implant for Treatment of Patients with Persistent Diabetic Macular Edema

Intravitreal Dexamethasone Implant in Patients with Persistent Diabetic Macular Edema

Contact Info

Product

Resources

About